Outlook TherapeuticsOTLK
13F holders, Q3 2024 (September 30)1holders
0new positions
0sold out
$5.34avg. 13F price*
At the end of Q3 2024, 1 institutions reported holding Outlook Therapeutics Inc. (OTLK) in their 13F filings, unchanged from Q2 2024. 0 opened new positions and 0 sold out. The largest holder was Rosalind Advisors, Inc. ($2.4M).
- Company
- Outlook Therapeutics Inc.
- CUSIP
- 69012T206
- Latest filing quarter
- Q3 2024
History
Number of 13F holders
Total Exit/New Position Q2 2024 → Q3 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 0 | $0 |
| Exits | 0 | $0 |
Ownership 1 holders
| Rosalind Advisors, Inc. | 1.59% | No change | 450,000 | $2.4M |
"% of holder's portfolio" is OTLK's weight in each manager's 13F, not the share of Outlook Therapeutics Inc. the manager owns.